Republic Technologies Announces Drawdown of US$10 Million Principal Amount First Tranche Under US$100 Million Secured Convertible Note Facility

Republic Technologies Announces Drawdown of US$10 Million Principal Amount First Tranche Under US$100 Million Secured Convertible Note Facility

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Republic Technologies Inc. (CSE: DOCT,OTC:DOCKF) (FSE: 7FM0) (WKN: A41AYF) (OTCQB: DOCKF) (the " Company " or " Republic ") is pleased to announce that, further to its news release dated November 20, 2025, it has closed the first drawdown (the " First Drawdown ") of its previously announced secured convertible note facility of up to US$100 million (the " Convertible Facility "), for gross proceeds of US$10 million less the original issue discount.

The First Drawdown was completed on a non-brokered private placement basis. Upon closing, 10,000 convertible notes, each with a principal amount of US$1,000 (the " First Drawdown Convertible Notes "), were issued.

The First Drawdown Convertible Notes are secured pursuant to a security agreement over a custody account (the " Custody Account "), with a fixed number of ETH as collateral (the " ETH Target "), equal to US$12 million. The ETH Target will remain fixed for the duration of the Convertible Facility. The Company intends to allocate approximately 90% of the net proceeds from the First Drawdown toward the acquisition of ETH to support Republic's validator infrastructure and attestation services, with the balance to be used for general working capital purposes.

In connection with the First Drawdown, the Company issued 27,904,000 common share purchase warrants (the " First Drawdown Warrants "), each exercisable to purchase one Common Share at a price of C$0.50 per Common Share (185% of current market price) for a period of 5 years from the date of issuance. If fully exercised, the First Drawdown Warrants would provide the Company with approximately an additional US$10 million in financing.

No insiders of the Company participated in the First Drawdown, and no new control person was created as a result of the First Drawdown. Shareholder approvals for the Convertible Facility, as required by applicable CSE policy, were obtained prior to the closing of the First Drawdown.

The First Drawdown Convertible Notes, the First Drawdown Warrants, and any Common Shares issuable upon conversion of the First Drawdown Convertible Notes or exercise of the First Drawdown Warrants are subject to a statutory hold period of four months plus one day in accordance with applicable Canadian securities laws.

Additional terms of the Convertible Facility are available in the Company's October 20 and November 20, 2025 news releases, and a copy of the Convertible Facility agreement has been filed on the Company's SEDAR+ profile at www.sedarplus.ca .

About Republic Technologies Inc.

Republic Technologies is a publicly traded technology company integrating Ethereum infrastructure into the global economy. Backed by an ETH-denominated treasury, we operate validator and attestation networks to safeguard data integrity for universal applications.

Forward-Looking Statements

This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, statements regarding the subsequent drawdowns and Top-Up Tranches, expected timing, anticipated closing(s) of the subsequent drawdown(s) and Top-Up Tranche(s), anticipated CSE approvals, and the intended use of proceeds. Forward-looking information is based on management's reasonable assumptions as of the date hereof, including assumptions regarding market conditions, the Company's ability to obtain required approvals (including CSE approval), and operate its validator infrastructure as intended. Forward-looking information is inherently subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including the risk that the subsequent drawdowns and Top-Up Tranches do not proceed on the terms described or at all; failure to obtain subsequent CSE approvals; failure to satisfy other closing conditions; third-party, counterparty or lender consent requirements; volatility in ETH prices and staking yields; evolving regulatory developments affecting digital assets and staking; operational risks related to validator performance, slashing and custody, and other factors described under the Company's public disclosure filings available on SEDAR+ at www.sedarplus.ca . Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the accuracy or adequacy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.

On behalf of the Board of Directors
Daniel Liu,
Chief Executive Officer
Tel: (778) 200-4124
Email: info@republictech.io
https://republictech.io/

News Provided by Business Wire via QuoteMedia

DOCT:CNX
The Conversation (0)
beyond medical

Beyond Medical Technologies

Keeping Canadians Healthy and Safe

Keeping Canadians Healthy and Safe Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...
Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News